Report Detail
Global (United States, European Union and China) Systemic Lupus Erythematosus (SLE) Drugs Market Research Report 2019-2025
- RnM3685629 |
- 20 August, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.
In 2019, the market size of Systemic Lupus Erythematosus (SLE) Drugs is 170 million US$ and it will reach 280 million US$ in 2025, growing at a CAGR of 6.8% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Systemic Lupus Erythematosus (SLE) Drugs.
This report studies the global market size of Systemic Lupus Erythematosus (SLE) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Systemic Lupus Erythematosus (SLE) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Anthera Pharmaceuticals
GSK
ImmuPharma
Johnson & Johnson
...
Market Segment by Product Type
Corticosteroids
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Anti-Inflammatories
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Antimalarials
BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
Immunosuppressive Agents/Immune Modulators
Anticoagulants
Market Segment by Application
Intravenous
Sub-Cutaneous
Oral
Topical
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Systemic Lupus Erythematosus (SLE) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Systemic Lupus Erythematosus (SLE) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Systemic Lupus Erythematosus (SLE) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Corticosteroids
- 1.3.3 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- 1.3.4 Anti-Inflammatories
- 1.3.5 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- 1.3.6 Antimalarials
- 1.3.7 BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
- 1.3.8 Immunosuppressive Agents/Immune Modulators
- 1.3.9 Anticoagulants
- 1.4 Market Segment by Application
- 1.4.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Share by Application (2019-2025)
- 1.4.2 Intravenous
- 1.4.3 Sub-Cutaneous
- 1.4.4 Oral
- 1.4.5 Topical
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size
- 2.1.1 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue 2014-2025
- 2.1.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales 2014-2025
- 2.2 Systemic Lupus Erythematosus (SLE) Drugs Growth Rate by Regions
- 2.2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Regions 2014-2019
- 2.2.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Systemic Lupus Erythematosus (SLE) Drugs Sales by Manufacturers
- 3.1.1 Systemic Lupus Erythematosus (SLE) Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Systemic Lupus Erythematosus (SLE) Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Systemic Lupus Erythematosus (SLE) Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Systemic Lupus Erythematosus (SLE) Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Systemic Lupus Erythematosus (SLE) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Systemic Lupus Erythematosus (SLE) Drugs Price by Manufacturers
- 3.4 Key Manufacturers Systemic Lupus Erythematosus (SLE) Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Systemic Lupus Erythematosus (SLE) Drugs Market
- 3.6 Key Manufacturers Systemic Lupus Erythematosus (SLE) Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Corticosteroids Sales and Revenue (2014-2019)
- 4.1.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Sales and Revenue (2014-2019)
- 4.1.3 Anti-Inflammatories Sales and Revenue (2014-2019)
- 4.1.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Sales and Revenue (2014-2019)
- 4.1.5 Antimalarials Sales and Revenue (2014-2019)
- 4.1.6 BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS) Sales and Revenue (2014-2019)
- 4.1.7 Immunosuppressive Agents/Immune Modulators Sales and Revenue (2014-2019)
- 4.1.8 Anticoagulants Sales and Revenue (2014-2019)
- 4.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Market Share by Type
- 4.3 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue Market Share by Type
- 4.4 Systemic Lupus Erythematosus (SLE) Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Application
6 United States
- 6.1 United States Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Company
- 6.2 United States Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Type
- 6.3 United States Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Company
- 7.2 European Union Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Type
- 7.3 European Union Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Application
8 China
- 8.1 China Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Company
- 8.2 China Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Type
- 8.3 China Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Company
- 9.2 Rest of World Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Type
- 9.3 Rest of World Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Application
- 9.4 Rest of World Systemic Lupus Erythematosus (SLE) Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Systemic Lupus Erythematosus (SLE) Drugs Sales by Countries
- 9.4.2 Rest of World Systemic Lupus Erythematosus (SLE) Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Anthera Pharmaceuticals
- 10.1.1 Anthera Pharmaceuticals Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Systemic Lupus Erythematosus (SLE) Drugs
- 10.1.4 Systemic Lupus Erythematosus (SLE) Drugs Product Introduction
- 10.1.5 Anthera Pharmaceuticals Recent Development
- 10.2 GSK
- 10.2.1 GSK Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Systemic Lupus Erythematosus (SLE) Drugs
- 10.2.4 Systemic Lupus Erythematosus (SLE) Drugs Product Introduction
- 10.2.5 GSK Recent Development
- 10.3 ImmuPharma
- 10.3.1 ImmuPharma Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Systemic Lupus Erythematosus (SLE) Drugs
- 10.3.4 Systemic Lupus Erythematosus (SLE) Drugs Product Introduction
- 10.3.5 ImmuPharma Recent Development
- 10.4 Johnson & Johnson
- 10.4.1 Johnson & Johnson Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Systemic Lupus Erythematosus (SLE) Drugs
- 10.4.4 Systemic Lupus Erythematosus (SLE) Drugs Product Introduction
- 10.4.5 Johnson & Johnson Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Systemic Lupus Erythematosus (SLE) Drugs Sales Channels
- 11.2.2 Systemic Lupus Erythematosus (SLE) Drugs Distributors
- 11.3 Systemic Lupus Erythematosus (SLE) Drugs Customers
12 Market Forecast
- 12.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Forecast by Type
- 12.3 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Forecast by Application
- 12.4 Systemic Lupus Erythematosus (SLE) Drugs Forecast by Regions
- 12.4.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Systemic Lupus Erythematosus (SLE) Drugs. Industry analysis & Market Report on Systemic Lupus Erythematosus (SLE) Drugs is a syndicated market report, published as Global (United States, European Union and China) Systemic Lupus Erythematosus (SLE) Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Systemic Lupus Erythematosus (SLE) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
